A Phase I Study Investigating the Combination of RAD001 With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Overview
- Phase
- Phase 1
- Intervention
- cytarabine
- Conditions
- Leukemia
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
- Enrollment
- 11
- Locations
- 5
- Primary Endpoint
- Maximum-tolerated dose of everolimus
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
RATIONALE: Drugs used in chemotherapy, such as mitoxantrone hydrochloride, cytarabine, etoposide, and idarubicin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Giving everolimus together with combination chemotherapy may kill more cancer cells.
PURPOSE: This phase I trial is studying the side effects and best dose of everolimus when given together with mitoxantrone hydrochloride, cytarabine, etoposide, and idarubicin in treating older patients with newly diagnosed acute myeloid leukemia.
Detailed Description
OBJECTIVES: Primary * To determine the maximum-tolerated dose of everolimus in combination with standard remission-induction therapy comprising mitoxantrone hydrochloride, cytarabine, and etoposide (MICE-regimen) followed by consolidation therapy comprising idarubicin, cytarabine, and etoposide in older patients with newly diagnosed acute myeloid leukemia. Secondary * To determine the safety profile of this regimen in these patients. * To determine the anti-leukemic activity (complete remission rate \[complete remission and complete remission with incomplete blood count recovery\]) following one or two induction courses. OUTLINE: This is a multicenter, dose-escalation study of everolimus. * Standard remission-induction therapy: Patients receive mitoxantrone hydrochloride IV over 30 minutes on days 1, 3, and 5; cytarabine IV continuously on days 1-7; etoposide IV over 1 hour on days 1-3; and oral everolimus once a day on days 1-21. Patients with partial remission (PR) receive a second induction course, beginning 7-17 days after completion of induction course 1. Patients with complete remission or complete remission with incomplete blood count recovery (CR/CRi) after induction therapy proceed to consolidation therapy; patients who have failed to achieve PR after induction course 1 or a CR/CRi after induction course 2 are removed from study. * Consolidation therapy: Beginning within 3 weeks from CR/CRi documentation, patients receive idarubicin IV over 30 minutes on days 1, 3, and 5; cytarabine IV continuously on days 1-5; etoposide IV over 1 hour on days 1-3; and oral everolimus once a day on days 1-10. Patients may receive another course of the consolidation therapy, beginning at least 4 weeks after initiation of consolidation therapy course 1. After completion of study treatment, patients are followed up once a month for 1 year, every 3 months for 1 year, and then periodically thereafter.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Arms & Interventions
Everolimus
Everolimus mice-regimen
Intervention: cytarabine
Everolimus
Everolimus mice-regimen
Intervention: etoposide
Everolimus
Everolimus mice-regimen
Intervention: everolimus
Everolimus
Everolimus mice-regimen
Intervention: idarubicin
Everolimus
Everolimus mice-regimen
Intervention: mitoxantrone hydrochloride
Outcomes
Primary Outcomes
Maximum-tolerated dose of everolimus
Time Frame: At one year from study entry
MTD of RAD given in combination with the MICE regimen
Secondary Outcomes
- Safety(At one year from study entry)
- Complete remission rate(At one year from study entry)